Contact us for more information on the VAL-083 Clinical Trials

I am a:

Clinical Trials for VAL-083

VAL-083 is a structurally unique, "first-in-class", small-molecule chemotherapeutic. Based on historical data and our own research, we believe that VAL-083 has the potential to offer physicians and patients a new paradigm in the treatment of Glioblastoma Multiforme (GBM).

The safety and efficacy of the investigational use of this product has not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.